Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 664-669, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tripodi, A.
Right arrow Articles by Mannucci, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tripodi, A.
Right arrow Articles by Mannucci, P. M.

Clinical Chemistry, Vol 42, 664-669, Copyright © 1996 by American Association for Clinical Chemistry

Markers of activated coagulation and their usefulness in the clinical laboratory

A Tripodi and PM Mannucci
Institute of Internal Medicine, IRCCS Maggiore University, Milano, Italy.

Currently, information on hypercoagulability can be achieved directly-- through measuring the enzymatic forms of coagulation zymogens generated during coagulation activation--or indirectly--through measuring the activation peptides generated when zymogens are activated or the enzyme- inhibitor complexes formed by inhibition of the enzymes by their plasmatic inhibitors. On the basis of published results, markers of activated coagulation are considered useful for investigating mechanisms that regulate hemostasis. They can also be used to better characterize patients at increased thrombotic risk. However, they should be considered indices of hypercoagulability, not of the risk of thrombosis, until prospective studies can demonstrate that alterations of these markers can predict the occurrence of thrombosis. For diagnosing acute thrombosis, their usefulness is questionable; they are less effective than markers of fibrinolysis activation such as the D- dimer. Finally, their use to monitor anticoagulant treatment is still premature and needs investigation in well-designed clinical studies.


The following articles in journals at HighWire Press have cited this article:


Home page
 CJASNHome page
H. Wu, D. J. Birmingham, B. Rovin, K. V. Hackshaw, N. Haddad, D. Haden, C.-Y. Yu, and L. A. Hebert
D-Dimer Level and the Risk for Thrombosis in Systemic Lupus Erythematosus
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1628 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. Solymoss
Risk factors for thromboembolism: pathophysiology and detection
Can. Med. Assoc. J., October 1, 2000; 163(8): 991 - 994.
[Full Text] [PDF]

Home page
 HeartHome page
R C van Nieuwenhuizen, M Peters, L J Lubbers, M D Trip, J G P Tijssen, and B J M Mulder
Abnormalities in liver function and coagulation profile following the Fontan procedure
Heart, July 1, 1999; 82(1): 40 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. T. Hermens, M. M. A. L. Pelsers, M.-L. Mullers-Boumans, C. de Zwaan, and J. F. C. Glatz
Combined Use of Markers of Muscle Necrosis and Fibrinogen Conversion in the Early Differentiation of Myocardial Infarction and Unstable Angina
Clin. Chem., April 1, 1998; 44(4): 890 - 892.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. A. Merlini, D. Ardissino, K. A. Bauer, L. Oltrona, A. Pezzano, B. Bottasso, R. D. Rosenberg, and P. M. Mannucci
Persistent Thrombin Generation During Heparin Therapy in Patients With Acute Coronary Syndromes
Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1325 - 1330.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.